23andMe: The Ethics of Genetic Testing for Neurodegenerative Diseases
The following post is part of a special series emerging from Contemporary Issues in Neuroethics, a graduate-level course out of Emory University’s Center for Ethics. Liana is a senior at Emory University majoring in Neuroscience and Behavioral Biology and Creative Writing (poetry). She is currently applying to Public Health graduate schools and considering a future in medicine. In her free time she enjoys running, reading, and her research on PTSD at Grady Memorial Hospital.
The face of genetic testing and counseling is in the midst of a major overhaul. Historically, a patient had to demonstrate several risk factors including familial and medical health history or early symptoms in order to be tested for the likelihood of developing a neurodegenerative disease. For the first time, the public has unrestricted and unregulated access to the relative probability of developing certain neurodegenerative diseases.
Want to cite this post?
Meffert, L. (2015). 23andMe: The Ethics of Genetic Testing for Neurodegenerative Diseases. The Neuroethics Blog. Retrieved on , from http://www.theneuroethicsblog.com/2015/05/23andme-ethics-of-genetic-testing-for.html